A classic smooth muscle marker

Calponin is an actin-binding protein originally identified in smooth muscle tissue. The most studied isoform, calponin 1 (CNN1), is highly specific to differentiated SMCs¹. It stabilizes the actin cytoskeleton and inhibits actomyosin ATPase activity, helping regulate muscle contraction. Because of its selective expression, CNN1 has long been used to define the smooth muscle phenotype in vascular tissues. Unlike early embryonic markers or transiently expressed contractile proteins, calponin maintains relatively stable expression in mature, differentiated SMCs.

Calponin in vascular biology, differentiation, and plasticity

SMCs aren't static. They can switch between a contractile phenotype (important for vascular tone) and a synthetic phenotype (important for repair and remodeling)². Calponin levels decrease during phenotypic modulation, making it a sensitive marker for vascular plasticity³. Researchers studying developmental biology, vascular injury, or arterial remodeling frequently track calponin alongside transcriptional regulators like myocardin. Monitoring changes in calponin expression helps reveal when SMCs shift from a quiescent to a proliferative, matrix-producing state⁴.

Calponin as a cardiovascular disease marker

The loss or modulation of calponin expression has been documented in several vascular diseases:

●       Atherosclerosis: During plaque formation, vascular SMCs (VSMCs) undergo phenotypic switching from a contractile to a synthetic state, marked by reduced expression of calponin. This downregulation enables VSMC migration and proliferation into the intima. Alongside other markers, calponin measurement can help distinguish synthetic SMCs from inflammatory and endothelial-like cells in advanced lesions.^5–7

●       Restenosis: Following vascular interventions such as angioplasty or stenting, VSMCs contribute to neointimal hyperplasia through proliferation and dedifferentiation. Calponin serves as a useful marker to track VSMC re-differentiation during vessel healing. Sustained calponin expression is associated with a more stable, differentiated VSMC phenotype and may correlate with reduced neointimal growth and improved vascular remodeling.^8,9

●       Aneurysms: In aneurysm-prone vessels, decreased calponin expression reflects the loss of VSMC contractile phenotype, a change associated with vessel wall weakening. This phenotypic modulation contributes to structural instability and is thought to play a key role in the development and potential rupture of aneurysms.¹⁰

In these contexts, calponin provides a molecular window into SMC behavior across several vascular pathologies.

Other smooth muscle markers

Calponin is part of a broader family of smooth muscle markers, each reflecting different stages of SMC differentiation and function. Below is a quick summary of the strengths and limitations of the most common markers used in SMC research:

Because no single marker perfectly defines SMCs under all conditions, modern studies typically use a combination of early and late markers — often pairing calponin with SM22α or Myh11 — to capture a more complete view of SMC identity and plasticity.

Selecting the right marker for your research depends on what aspect of SMC biology you're studying. Here's a quick guide to popular marker choices for common research needs:

From fundamentals to the frontier

Calponin’s continued relevance is partly due to its use in emerging research fields.  By providing insight into smooth muscle differentiation and plasticity, calponin not only informs foundational research but also supports more advanced techniques like the development of engineered vascular tissues. Here, confirming true SMC identity is critical, and researchers differentiating stem cells into SMC-like cells use markers like calponin to assess success.¹¹

Beyond CNN1, researchers are also investigating the roles of calponin’s other isoforms, calponin 2 (CNN2) and calponin 3 (CNN3), in the vasculature and other tissues¹. While CNN1 is smooth muscle–specific, CNN2 and CNN3 have broader expression profiles and may play complementary roles in cytoskeletal organization during inflammation, wound healing, mechanotransduction, and cell migration¹²​.

A cornerstone marker with modern relevance

Despite being discovered almost four decades ago¹³, calponin continues to be a powerful tool for cardiovascular researchers. Whether you're investigating smooth muscle development, tracking phenotypic switching in disease, or validating engineered tissue constructs, calponin remains one of the most reliable markers of the contractile smooth muscle phenotype. Its nuanced expression patterns offer insight into plasticity and pathology, while its compatibility with other markers makes it a staple in complex multi-marker panels.

As new technologies advance vascular biology, calponin remains a molecular mainstay, bridging foundational science and translational research to improve cardiovascular outcomes.

References:

1. Liu, R. & Jin, J.-P. Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskeleton functions in smooth muscle and non-muscle cells. Gene 585, 143–153 (2016).

2. Liao, X.-H. et al. STAT3 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. J. Biol. Chem. 290, 19641–19652 (2015).

3. Yamamura, H. et al. Structure and expression of calponin in arterial smooth muscle cells. In The Ischemic Heart (eds Mochizuki, S., Takeda, N., Nagano, M. & Dhalla, N. S.) 87–95 (Springer US, 1998).

4. Gomez, D. & Owens, G. K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 95, 156–164 (2012).

5. Zhou, Z.-X. et al. TRIM65 promotes vascular smooth muscle cell phenotypic transformation by activating PI3K/Akt/mTOR signaling during atherogenesis. Atherosclerosis 390, 117430 (2024).

6. Yu, Y. et al. Vascular smooth muscle cell phenotypic switching in atherosclerosis. Heliyon 10, e37727 (2024).

7. Rzucidlo, E. M., Martin, K. A. & Powell, R. J. Regulation of vascular smooth muscle cell differentiation. J. Vasc. Surg. 45, A25–A32 (2007).

8. Zhu, Q. et al. Intermedin reduces neointima formation by regulating vascular smooth muscle cell phenotype via cAMP/PKA pathway. Atherosclerosis 266, 212–222 (2017).

9. Wu, J. et al. Semaphorin-3A protects against neointimal hyperplasia after vascular injury. EBioMedicine 39, 95–108 (2019).

10. Starke, R. M. et al. Vascular smooth muscle cells in cerebral aneurysm pathogenesis. Transl. Stroke Res. 5, 338–346 (2014).

11. Dash, B. C. Tissue-engineered vascular rings from human iPSC-derived smooth muscle cells. [No journal info provided—cannot complete citation in Nature style.]

12. Nguyen, M. T. et al. Calponin 3 regulates myoblast proliferation and differentiation through actin cytoskeleton remodeling and YAP1-mediated signaling in myoblasts. Cells 14, 142 (2025).

13. Winder, S. J., Sutherland, C. & Walsh, M. P. Biochemical and functional characterization of smooth muscle calponin. In Regulation of Smooth Muscle Contraction (ed Moreland, R. S.) 37–51 (Springer US, 1991).

Related resources